Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CerusCERS +0.55%78 OCF Margin % is -4.63% as of Jun. 2026. GuruFocus rates CERS with a GF Score™ of 78/100 and a GF Value™ of $2.23 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Cerus ranks worse than 58.67% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Cerus's Cash Flow from Operations for the
three
months ended in Jun. 2026 was $-2.7 Mil. Cerus's Revenue for the
three
months ended in Jun. 2026 was $57.4 Mil. Therefore, Cerus's OCF Margin % for the quarter that ended in Jun. 2026 was -4.63%.
The historical data trend for Cerus's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cerus's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Cerus's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (CERS) has a OCF Margin % of -4.63% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cerus and its competitors. According to the industry distribution chart, Cerus ranks #477 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 58.7%.
Is Cerus' OCF Margin % too high?
Cerus' current OCF Margin % is -4.63%. Based on the distribution chart, Cerus ranks #477 out of 813 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cerus has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cerus' OCF Margin % compare to CTKB and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cerus ranks #477 out of 813 companies for OCF Margin %. This places Cerus in the lower half of its industry. The industry median OCF Margin % is 5.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.99, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cerus and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cerus's current OCF Margin % is -4.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cerus stock overvalued right now?
Based on GuruFocus' analysis, Cerus (CERS) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.23, compared to a current price of $2.74 — trading 22.9% above its estimated fair value. The current OCF Margin % is -4.63%. Cerus' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Cerus (CERS), the current OCF Margin % is -4.63% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cerus (CERS) Overvalued in 2026?
Based on GuruFocus' analysis, Cerus stock appears to be overvalued.
The current stock price of $2.74 is trading 22.9% above its estimated GF Value™ of $2.23.
GuruFocus considers Cerus to be Modestly Overvalued.
Key valuation signals for CERS:
OCF Margin %: -4.63%
GF Value™: $2.23 vs. price of $2.74 (22.9% above fair value)
No single metric tells the full story. See the CERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score
Get the complete analysis for CERS
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERS has been successfully added to your 
